A gene that regulates the development of roots in vascular plants is also involved in the organ development of ...

Memorial Sloan Kettering Cancer Center investigators report that T cell interferon-γ (IFNγ) orchestrates a dendritic-cell–natural-killer-cell circuit that suppresses leptomeningeal metastases in mouse ...

As people age, their immune systems become less efficient, posing a challenge for cancer therapies that rely on harnessing ...

Mitochondria turn the food we eat into the energy our cells can use. But when stress hijacks the process they use to maintain ...

A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory ...

Recludix Pharma, a leader in the discovery of inhibitors for challenging targets in inflammatory disease, today announced a ...

In recent years, the therapeutic landscape for hematological malignancies has undergone a profound transformation, driven by ...

Those problems mean that so far only one T-cell engager has reached the market – Amgen’s Blincyto (blinatumomab) for leukaemia – although many others are coming through development.

Here the authors use both patient data and a mouse glomerulonephritis model to show that increased type I interferon may expand a subset of pro-inflammatory T cells for subsequent kidney pathology.

Marvel Rivals’ game director and others from the development team behind the hit ... who join me in this sad culling. Just couldn’t dodge that big boot I guess, no matter how big the success ...